Effects of Short-Term Propylthiouracil Treatment on P Wave Duration and P Wave Dispersion in Patients with Overt Hypertyroidism

 

 Buy Article Permissions and Reprints

Abstract

Background: P-wave duration is defined as the time measured from the onset to the offset of the P-wave in surface electrocardiogram (ECG). Prolonged P wave duration and increased P wave dispersion (PWD) have been reported to carry an increased risk for atrial fibrillation.

Aim: Our aim was to evaluate the role of hyperthyroidism on P wave duration and dispersion, to investigate the effect of anti-thyroid therapy on P wave duration and dispersion.

Material and methods: A total of 44 consecutive subjects (22 patients with newly diagnosed overt hyperthyroidism and 22 randomly selected euthyroid healthy subjects) were enrolled in the study. Transthoracic echocardiography, 12 lead surface ECG and thyroid hormone levels were studied at the time of enrollment, in the first and third months of the 6-8 mg/kg/day propylthiouracil therapy. Patients were followed-up for 3 months.

Results: Patient and control groups were consisted of age and sex matched subjects. Baseline left atrial diameter was similar between the patient and control groups (3.4±0.3 cm and 3.4±0.3 cm respectively, p=0.813). The maximum P-wave duration (P maximum) was 113.1±6.6 and 105.7±4.1 ms in patient and control groups (p=0.001). PWD was 31.5±9.5 and 25.2±5.9 ms in patient and control groups respectively (p=0.015). At the third month of propylthiouracil treatment P maximum and PWD were decreased in the patient group at statistically significant level and returned back in normal limits (p<0.001 and p=0.001).

Conclusion: P wave duration and PWD are found prolonged in hyperthyroid patients and propylthiouracil treatment decreased them effectively. This mechanism may establish how the anti-thyroid treatment may prevent the development of atrial fibrillation in hyperthyroid patients.

References

• 1 Klein I, Ojamaa K. Thyrotoxicosis and the heart.  Endocrinol Metab Clin North Am. 1998;  27 51-62
  CrossrefPubMedGoogle Scholar
• 2 Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a reversible cause of “idiopathic” atrial fibrillation.  Am J Cardiol. 1979;  44 9-12
  CrossrefPubMedGoogle Scholar
• 3 Gilligan DM, Ellenbogen KA, Epstein AE. The management of atrial fibrillation.  Am J Med. 1996;  101 413-421
  CrossrefPubMedGoogle Scholar
• 4 Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.  N Eng J Med. 1994;  331 1249-1252
  CrossrefPubMedGoogle Scholar
• 5 Dilaveris PE, Gialafos EJ, Sideris SK, Theopistou AM, Andrikopoulos GK, Kyriakidis M, Gialafos JE, Toutouzas PK. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation.  Am Heart J. 1998;  135 733-738
  CrossrefPubMedGoogle Scholar
• 6 Aytemir K, Ozer N, Atalar E, Sade E, Aksoyek S, Ovunc K, Acil T, Nazli N, Ozmen F, Oto A, Kes S. P-wave dispersion on 12-lead electrocardiogram in patients with paroxysmal atrial fibrillation.  Pacing Clinical Electrophysiology. 2000;  23 1109-1112
  PubMedGoogle Scholar
• 7 Steinberg JS, Zelenkofske S, Wong SC, Gelernt M, Sciacca R, Menchavez E. Value of P wave signal-averaged ECG for predicting atrial fibrillation after cardiac surgery.  Circulation. 1993;  88 1622-2618
  PubMedGoogle Scholar
• 8 Dilaveris PE, Gialafos EJ, Andrikopoulos GK, Richter DJ, Papanikolaou V, Poralis K, Gialafos JE. Clinical and electrocardiographic predictors of recurrent atrial fibrillation.  Pacing Clinical Electrophysiology. 2000;  23 352-358
  PubMedGoogle Scholar
• 9 Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system.  N Engl J Med. 2001;  344 501-509
  CrossrefPubMedGoogle Scholar
• 10 Ma ML, Watanabe K, Watanabe H, Hosaka Y, Komura S, Aizawa Y, Yamamoto T. Different gene expression of potassium channels by thyroid hormone and an antithyroid drug between the atrium and ventricle of rats.  Jpn Heart J. 2003;  44 101-110
  CrossrefPubMedGoogle Scholar
• 11 Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state.  Am J Med. 1982;  72 903-906
  CrossrefPubMedGoogle Scholar
• 12 Moe GK, Abildskov JA. Atrial fibrillation as a self sustaining arrhythmia independent of focal discharge.  Am Heart J. 1959;  58 59-70
  CrossrefPubMedGoogle Scholar
• 13 Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs.  Circ Res. 1988;  62 395-410
  PubMedGoogle Scholar
• 14 Cetinarslan B, Akkoyun M, Canturk Z, Tarkun I, Kahranman G, Komsuoglu B. Duration of the P wave and P wave dispersion in subclinical hyperthyroidism.  Endocr Pract. 2003;  9 200-203
  PubMedGoogle Scholar
• 15 Aras D, Maden O, Ozdemir O, Aras S, Topaloglu S, Yetkin E, Demir AD, Soylu MO, Erdogan MF, Kisacik HL, Korkmaz S. Simple electrocardiographic markers for the prediction of paroxysmal atrial fibrillation in hyperthyroidism.  Int J Cardiol. 2005;  99 59-64
  CrossrefPubMedGoogle Scholar
• 16 Cooper DS. Antithyroid drugs.  N Engl J Med. 2005;  352 905-917
  CrossrefPubMedGoogle Scholar

Correspondence

F. Deniz

Etimesgut Military Hospital

Department of Endocrinology and Metabolism

Ankara

Turkey

Ust Hava Lojmanlari A-7/7 Etimesgut Ankara

Turkey

Phone: +90/312/244 22 37

Fax: +90/312/473 61 88

Email: bpamukcu@gmail.com

Email: mtuna89@yahoo.com

Email: ferhatdeniz20@yahoo.com